JPWO2006090689A1 - Siv−pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 - Google Patents
Siv−pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 Download PDFInfo
- Publication number
- JPWO2006090689A1 JPWO2006090689A1 JP2007504715A JP2007504715A JPWO2006090689A1 JP WO2006090689 A1 JPWO2006090689 A1 JP WO2006090689A1 JP 2007504715 A JP2007504715 A JP 2007504715A JP 2007504715 A JP2007504715 A JP 2007504715A JP WO2006090689 A1 JPWO2006090689 A1 JP WO2006090689A1
- Authority
- JP
- Japan
- Prior art keywords
- vector
- pedf
- siv
- gene
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 title claims abstract description 337
- 201000010099 disease Diseases 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 23
- 230000001640 apoptogenic effect Effects 0.000 title claims abstract description 19
- 230000007850 degeneration Effects 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims abstract description 62
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 40
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 28
- 210000001519 tissue Anatomy 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 127
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 74
- 238000012546 transfer Methods 0.000 claims description 69
- 238000004806 packaging method and process Methods 0.000 claims description 62
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 229940127557 pharmaceutical product Drugs 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000002207 retinal effect Effects 0.000 claims description 5
- 201000007737 Retinal degeneration Diseases 0.000 claims description 4
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 208000023589 ischemic disease Diseases 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 abstract description 29
- 208000005400 Synovial Cyst Diseases 0.000 abstract description 29
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract description 22
- 230000000302 ischemic effect Effects 0.000 abstract description 14
- 230000010410 reperfusion Effects 0.000 abstract description 13
- 230000030833 cell death Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000001629 suppression Effects 0.000 abstract description 2
- 238000002716 delivery method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 123
- 239000012634 fragment Substances 0.000 description 28
- 239000002245 particle Substances 0.000 description 26
- 238000011282 treatment Methods 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 20
- 239000002609 medium Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 17
- 239000013603 viral vector Substances 0.000 description 17
- 239000002585 base Substances 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 206010063837 Reperfusion injury Diseases 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 102100034349 Integrase Human genes 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000003994 retinal ganglion cell Anatomy 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 101710177291 Gag polyprotein Proteins 0.000 description 9
- 101710149951 Protein Tat Proteins 0.000 description 9
- 230000004410 intraocular pressure Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 101710091045 Envelope protein Proteins 0.000 description 8
- 241000713666 Lentivirus Species 0.000 description 8
- 102000007072 Nerve Growth Factors Human genes 0.000 description 8
- 101710188315 Protein X Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000003900 neurotrophic factor Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108010089520 pol Gene Products Proteins 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000006366 primary open angle glaucoma Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000282537 Mandrillus sphinx Species 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010067013 Normal tension glaucoma Diseases 0.000 description 2
- 101710150344 Protein Rev Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 210000000782 cerebellar granule cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 201000002978 low tension glaucoma Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000032253 retinal ischemia Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 241001422755 Atys Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150019331 FGF2 gene Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108700010774 hepadnaviridae proteins Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000036460 primary closed-angle glaucoma Diseases 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(1)色素上皮由来因子(Pigment epithelium derived factor:PEDF)遺伝子を保持する組換えサル免疫不全ウイルスベクター、および薬学的に許容される媒体を含む、眼組織細胞におけるアポトーシス変性を伴う疾患の治療用医薬品、
(2)サル免疫不全ウイルスベクターがcPPT配列および/またはWPRE配列を含む、上記(1)に記載の医薬品、
(3)サル免疫不全ウイルスベクターがVSV-Gでシュードタイプ化されている、上記(1)または(2)に記載の医薬品、
(4)サル免疫不全ウイルスベクターがagm株由来である、上記(1)から(3)のいずれかに記載の医薬品、
(5)眼組織細胞におけるアポトーシス変性を伴う疾患が、緑内障、網膜色素変性、網膜剥離、網膜虚血性疾患のいずれかである、上記(1)から(4)のいずれかに記載の医薬品、
(6)PEDF遺伝子を保持する組換えサル免疫不全ウイルスベクターを投与する、眼組織細胞におけるアポトーシス変性を伴う疾患の治療方法、
(7)PEDF遺伝子を保持する組換えサル免疫不全ウイルスベクターを網膜下投与、硝子体内投与、または前房内投与する工程を含む、上記(6)に記載の方法。
(8)配列番号:1に記載の塩基配列にPEDF遺伝子が挿入された塩基配列を含むジーントランスファーベクターを用いる、上記(1)から上記(5)のいずれかに記載の医薬品の製造方法、
(9)配列番号:2に記載の塩基配列を含むジーントランスファーベクターを用いる、上記(8)に記載の医薬品の製造方法、
(10)配列番号:3に記載の塩基配列を含むパッケージングベクターが導入されたパッケージング細胞に該ジーントランスファーベクターを導入する工程を含む、上記(8)または上記(9)に記載の方法、
(11)配列番号:1記載の塩基配列または該配列中に外来遺伝子配列が挿入された配列を含む、サル免疫不全ウイルスのゲノムRNAをコードするベクター、
(12)外来遺伝子がPEDFである、上記(11)に記載のベクター、
(13)上記(11)または(12)に記載のベクターから転写されたゲノムRNAを含む、サル免疫不全ウイルス、
(14)VSV-Gでシュードタイプ化されている、上記(13)に記載のサル免疫不全ウイルス。
なお本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
ベクターの構築には図1に示す4種のプラスミド(ジーントランスファーベクター、パッケージングベクター、rev発現ベクター、VSV-G発現ベクター)を用いた。3種のジーントランスファーベクター、パッケージングベクター、rev発現ベクターについては、従来型のベクタープラスミド(PCT/JP00/03955)を改良して作製した。VSV-G発現ベクターについては従来のものをそのまま用いた。
従来型ジーントランスファーベクターに、cPTT(central polypurine tract)およびWPRE(woodchuck hepatitis virus posttranscriptional regulatory element)の導入を行い、ジーントランスファーベクターの性能改良を図った(図2A、B)。使用した従来型のジーントランスファーベクターは、非病原性のアフリカミドリザル免疫不全ウイルスのクローンであるSIVagmを基本とし、5’LTR領域、RRE、CMV(cytomegalovirus)プロモーター、EGFP(enhanced green fluorescent protein)遺伝子、3’LTRを順に有するベクターである。該従来型ジーントランスファーベクターは、本発明者らによって構築されたものであり、構築方法等については、既に報告済みである(特許文献2)。該従来型ジーントランスファーベクターの塩基配列を、配列番号:13に示す。
従来型パッケージングベクターにはgag,polの他に、修飾遺伝子と呼ばれるvif,vprと制御遺伝子のtat,revが含まれている。しかし、修飾遺伝子産物はベクターにおいて必要でないことが分かり(V.Kim et al.: J.Virol 72:811-816, 1998)、近年は、安全性を高めるため、修飾遺伝子が削除されたベクターが使用されている。また、tatも削除され、revは別のプラスミドに移すことにより更に安全性が高められた、第三世代と呼ばれるベクターが開発されており、現在ではベクターの第三世代化は必須となっている。そこで本発明においても、従来型パッケージングベクター(配列番号:27)から補助遺伝子(vif,vpr,tat)を取り除き、revを別のプラスミドに移し、安全性を高めることとした(図3)。方法は、基本的には、HIVベクターで以前に報告されている(T.Dull.et al.: J.Virol 72:8463-8471, 1998)。
rev蛋白はこれまで従来型のパッケージングベクターより供給されていたが、パッケージングベクターの上記改良に伴い、rev蛋白を別の発現プラスミドの形で供給することとし、新たに発現ベクターを構築した。revはゲノム上ではイントロンで2つに分かれているが、一つに結合して発現プラスミドに組み込むこととした(図4A、B)。
cPPT,WPREの導入の効果を調べるために、cPPT,WPRE同時搭載の他に、cPPT単独搭載、WPRE単独搭載のベクターを生産し、従来型のコントロールと比較した。全てのジーントランスファーベクターはEGFPを搭載しているものを用いた。パッケージングベクターは従来型(配列番号:27)を使用した。
ヒト胎児腎細胞由来細胞株293T細胞を15cmプラスチックシャーレ1枚あたり約1×107(翌日70-80%密度)になるように播種し、10%ウシ胎児血清を含むD-MEM培地(Gibco BRL)20mlで24時間培養した。24時間培養後、培地を10mlのOPTI-MEM培地(Gibco BRL)に置換して、細胞をトランスフェクトに用いた。
SIVベクターの力価には、搭載遺伝子蛋白の発現細胞数から算出する機能力価(Functional titer : TU/ml)とベクター粒子数から算出する値(Particle titer : particles/ml)がある。cPPT,WPREの性能評価はPartilce titerをそろえて細胞に感染させて評価するため、以下のようにドットブロッティングによる方法でParticle titerを測定した。
Particle titerを測定した4種類のベクターは、以下のようにMOI(multiplicity of infection)を変えて細胞に感染させ、FACS解析を行った。293T細胞を6ウェルのプラスチックカルチャープレートに1ウェルあたり1×106個で播き、37℃、5%CO2で一晩培養した。翌日、プレート1ウェルの細胞数を血球計数板で計算し、プレートの培地を除き、新しい10%ウシ胎児血清を含むD-MEM培地2mlで希釈したベクターをMOI(Particles/cell)が0.3、1.5、7.5、15になるように加えた。感染1日後、細胞の培地を2mlの新しいものと交換した。感染2日後、ベクターにより遺伝子導入されたEGFPを蛍光顕微鏡で観察し、EGFP陽性細胞の割合を測定し、更に蛍光強度(EGFP蛋白量の目安となる値)も測定した。
従来型のジーントランスファーベクターをコントロールとして、cPPT単独搭載、WPRE単独搭載、cPPT, WPRE同時搭載の4種類のベクターを生産した。ベクターデザインの模式図を図5-(a)に示す。
図1に示す改良型のジーントランスファーベクター、パッケージングベクター、rev発現ベクター、およびVSV-G発現ベクターの4種類のプラスミドをもとに以下のようにSIVベクターを調製した。PEDFの治療遺伝子を搭載したベクターは15cmシャーレ20枚単位で生産を行った。
緑内障モデル動物として虚血性再灌流モデルを作成し、SIV-PEDFベクターによる緑内障治療の可能性を検討した。まず、本発明のベクター:SIV-hPEDF、または外来遺伝子を持たない空ベクター: SIV-empty (2.5×107TU/ml、TU: transducing units)溶液を、4週齢のWistar 系ラットの網膜下腔に投与した。ベクター導入14日後に、上記ラットの眼内を110mmHgの圧にて60分間虚血状態とし、網膜神経節細胞を傷害した。障害4日後、脳定位固定装置を用いて蛍光色素DAPI(4',6-diamidino-2-phenylindole)を両上丘に注入し、神経節細胞を標識した。網膜神経節細胞障害7日後(ベクター導入21日後)に眼球を摘出し、flat mountにて蛍光顕微鏡で観察し、視神経から1mmの部位における1mm2当たりの標識神経節細胞数を計測した。
コントロールとして、ベクター溶液の代わりに網膜下腔にBSS溶液を投与され、虚血性再灌流障害処置されていない「ベクター非投与/非虚血再灌流障害群」、およびベクター溶液の代わりに網膜下腔にBSS溶液を投与され、虚血性再灌流障害処置された「ベクター非投与/虚血再灌流障害群」についても、蛍光顕微鏡による観察、および標識神経節細胞数の計測を同様の手順で行った。
緑内障モデル動物としてNMDA-inducedモデルを作成し、SIV-PEDFベクターによる緑内障治療の可能性を検討した。まず、本発明のベクターSIV-hPEDF、または外来遺伝子を持たない空ベクターSIV-empty (2.5×107TU/ml、TU: transducing units)溶液を、4週齢のWistar 系ラットの網膜下腔に投与した。ベクター導入14日後に、NMDA 40mM,5μlを硝子体内に投与して、神経節細胞層を選択的に傷害した。障害4日後、脳定位固定装置を用いて蛍光色素DAPI(4',6-diamidino-2-phenylindole)を両上丘に注入し、神経節細胞を標識した。網膜神経節細胞障害7日後(ベクター導入21日後)に眼球を摘出し、flat mountにて蛍光顕微鏡で観察し、視神経から1mmの部位における1mm2当たりの標識神経節細胞数を計測した。
コントロールとして、ベクター溶液の代わりに網膜下腔にBSS溶液を投与され、NMDA処置されていない「ベクター非投与/非NMDA-induced群」、およびベクター溶液の代わりに網膜下腔にBSS溶液を投与され、NMDA処置された「ベクター非投与/NMDA-induced群」についても、蛍光顕微鏡による観察、および標識神経節細胞数の計測を同様の手順で行った。
Claims (14)
- 色素上皮由来因子(Pigment epithelium derived factor:PEDF)遺伝子を保持する組換えサル免疫不全ウイルスベクター、および薬学的に許容される媒体を含む、眼組織細胞におけるアポトーシス変性を伴う疾患の治療用医薬品。
- サル免疫不全ウイルスベクターがcPPT配列および/またはWPRE配列を含む、請求項1に記載の医薬品。
- サル免疫不全ウイルスベクターがVSV-Gでシュードタイプ化されている、請求項1または2に記載の医薬品。
- サル免疫不全ウイルスベクターがagm株由来である、請求項1から3のいずれかに記載の医薬品。
- 眼組織細胞におけるアポトーシス変性を伴う疾患が、緑内障、網膜色素変性、網膜剥離、網膜虚血性疾患のいずれかである、請求項1から4のいずれかに記載の医薬品。
- PEDF遺伝子を保持する組換えサル免疫不全ウイルスベクターを投与する、眼組織細胞におけるアポトーシス変性を伴う疾患の治療方法。
- PEDF遺伝子を保持する組換えサル免疫不全ウイルスベクターを網膜下投与、硝子体内投与、または前房内投与する工程を含む、請求項6に記載の方法。
- 配列番号:1に記載の塩基配列にPEDF遺伝子が挿入された塩基配列を含むジーントランスファーベクターを用いる、請求項1から請求項5のいずれかに記載の医薬品の製造方法。
- 配列番号:2に記載の塩基配列を含むジーントランスファーベクターを用いる、請求項8に記載の医薬品の製造方法。
- 配列番号:3に記載の塩基配列を含むパッケージングベクターが導入されたパッケージング細胞に該ジーントランスファーベクターを導入する工程を含む、請求項8または請求項9に記載の方法。
- 配列番号:1記載の塩基配列または該配列中に外来遺伝子配列が挿入された配列を含む、サル免疫不全ウイルスのゲノムRNAをコードするベクター。
- 外来遺伝子がPEDFである、請求項11に記載のベクター。
- 請求項11または12に記載のベクターから転写されたゲノムRNAを含む、サル免疫不全ウイルス。
- VSV-Gでシュードタイプ化されている、請求項13に記載のサル免疫不全ウイルス。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007504715A JP4959547B2 (ja) | 2005-02-23 | 2006-02-21 | Siv−pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005047951 | 2005-02-23 | ||
JP2005047951 | 2005-02-23 | ||
PCT/JP2006/303032 WO2006090689A1 (ja) | 2005-02-23 | 2006-02-21 | Siv-pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 |
JP2007504715A JP4959547B2 (ja) | 2005-02-23 | 2006-02-21 | Siv−pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006090689A1 true JPWO2006090689A1 (ja) | 2008-07-24 |
JP4959547B2 JP4959547B2 (ja) | 2012-06-27 |
Family
ID=36927330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007504715A Active JP4959547B2 (ja) | 2005-02-23 | 2006-02-21 | Siv−pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8278284B2 (ja) |
EP (1) | EP1859813A1 (ja) |
JP (1) | JP4959547B2 (ja) |
KR (1) | KR20070114761A (ja) |
CN (1) | CN101180082B (ja) |
WO (1) | WO2006090689A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102010878B (zh) * | 2009-09-07 | 2013-06-19 | 复旦大学附属华山医院 | 携带视网膜色素上皮细胞衍生因子的超顺磁纳米载体 |
GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
WO2012126369A1 (zh) * | 2011-03-22 | 2012-09-27 | 北京三诺佳邑生物技术有限责任公司 | 核苷酸、包括其的重组载体、细胞、组合物及它们的应用 |
CN103060378A (zh) * | 2011-10-24 | 2013-04-24 | 四川百利药业有限责任公司 | 一种siv载体的制备方法 |
CN103316356B (zh) * | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
WO2017189715A1 (en) | 2016-04-26 | 2017-11-02 | Northwestern University | Modified pigment epithelium-derived factor (pedf) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1364197A (zh) | 1999-06-22 | 2002-08-14 | 株式会社载体研究所 | 用于表达两种外源基因的载体 |
CN100531802C (zh) * | 2000-06-01 | 2009-08-26 | 株式会社载体研究所 | 含有血凝素活性膜蛋白质的假型逆转录病毒载体 |
EP1403374A4 (en) | 2001-06-08 | 2004-07-21 | Dnavec Research Inc | GENE TRANSFER IN EMBRYONIC PRIMATE STEM CELLS WITH THE VSV-G PSEUDOTYPE MONKEY IMMUNITY WEAK VIRUS VECTOR |
AU2003225544A1 (en) * | 2002-02-04 | 2003-09-02 | Novartis Ag | Recombinant bovine immunodeficiency virus based gene transfer system |
EP1398041A1 (en) * | 2002-09-13 | 2004-03-17 | Université de Nantes | Recombinant lentiviral vector pseudotyped with the hemagglutinin protein for gene transfer into the retina |
-
2006
- 2006-02-21 WO PCT/JP2006/303032 patent/WO2006090689A1/ja active Application Filing
- 2006-02-21 EP EP06714172A patent/EP1859813A1/en not_active Withdrawn
- 2006-02-21 KR KR1020077021731A patent/KR20070114761A/ko active IP Right Grant
- 2006-02-21 CN CN2006800129054A patent/CN101180082B/zh active Active
- 2006-02-21 JP JP2007504715A patent/JP4959547B2/ja active Active
- 2006-02-21 US US11/884,738 patent/US8278284B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20090233988A1 (en) | 2009-09-17 |
US8278284B2 (en) | 2012-10-02 |
CN101180082B (zh) | 2012-02-08 |
CN101180082A (zh) | 2008-05-14 |
JP4959547B2 (ja) | 2012-06-27 |
KR20070114761A (ko) | 2007-12-04 |
EP1859813A1 (en) | 2007-11-28 |
WO2006090689A1 (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1895010B1 (en) | Equine infectious anaemia virus (eiav) based vectors | |
JP4861314B2 (ja) | 非組み込み型且つ非複製型組換えレンチウイルス、その調製および使用 | |
US7226780B2 (en) | Lentivirus vector system | |
EP2829285B1 (en) | Recombinant lentiviral vector preparation | |
Zhao et al. | Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo | |
US7179903B2 (en) | Liver specific transcriptional enhancer | |
CA2413995C (en) | Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity | |
JP4979851B2 (ja) | 高いタイターで安全な組換えレンチウイルスベクターの作製方法 | |
JP4959547B2 (ja) | Siv−pedfベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 | |
Bemelmans et al. | Retinal cell type expression specificity of HIV‐1‐derived gene transfer vectors upon subretinal injection in the adult rat: influence of pseudotyping and promoter | |
JP4971974B2 (ja) | Pedfおよびfgf2を含む眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 | |
WO2000040741A2 (en) | Lentivirus vector system | |
CA3177006A1 (en) | Compositions and methods for the treatment of cystic fibrosis | |
Ikeda et al. | Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure | |
US20060128019A1 (en) | Process for producing virus vector containing membrane protein having sialic acid-binding in envelope with the use of gram-positive bacterium origin nueraminidase | |
EP1398041A1 (en) | Recombinant lentiviral vector pseudotyped with the hemagglutinin protein for gene transfer into the retina | |
WO2005014836A2 (en) | Chimaeric vector system | |
GB2345062A (en) | Non-primate lentivirus retroviral vectors | |
US20110165683A1 (en) | Chimeric gammaretrovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20081031 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111014 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120220 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120321 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150330 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4959547 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |